Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

Barnes, DR; Silvestri, V; Leslie, G; McGuffog, L; Dennis, J; Yang, X; Adlard, J; Agnarsson, BA; Ahmed, M; Aittomaki, K; Andrulis, IL; Arason, A; Arnold, N; Auber, B; Azzollini, J; Balmana, J; Barkardottir, RB; Barrowdale, D; Barwell, J; Belotti, M; Benitez, J; Berthet, P; Boonen, SE; Borg, A; Bozsik, A; Brady, AF; Brennan, P; Brewer, C; Brunet, J; Bucalo, A; Buys, SS; Caldes, T; Caligo, MA; Campbell, I; Cassingham, H; Christensen, LL; Cini, G; Claes, KBM; GEMO Study Collaborators; EMBRACE Collaborators; Cook, J; Coppa, A; Cortesi, L; Damante, G; Darder, E; Davidson, R; de la Hoya, M; De Leeneer, K; De Putter, R; Del Valle, J; Diez, O; Ding, YC; Domchek, SM; Donaldson, A; Eason, J; Eeles, R; Engel, C; Evans, DG; Feliubadalo, L; Fostira, F; Frone, M; Frost, D; Gallagher, D; Gehrig, A; Giraud, S; Glendon, G; Godwin, AK; Goldgar, DE; Greene, MH; Gregory, H; Gross, E; Hahnen, E; Hamann, U; Hansen, TVO; Hanson, H; Hentschel, J; Horvath, J; kConFab Investigators; HEBON Investigators; Izatt, L; Izquierdo, A; James, PA; Janavicius, R; Jensen, UB; Johannsson, OT; John, EM; Kramer, G; Kroeldrup, L; Kruse, TA; Lautrup, C; Lazaro, C; Lesueur, F; Lopez-Fernandez, A; Mai, PL; Manoukian, S; Matrai, Z; Matricardi, L; Maxwell, KN; Mebirouk, N; Meindl, A; Montagna, M; Monteiro, AN; Morrison, PJ; Muranen, TA; Murray, A; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Nguyen-Dumont, T; Niederacher, D; Olah, E; Olopade, OI; Palli, D; Parsons, MT; Pedersen, IS; Peissel, B; Perez-Segura, P; Peterlongo, P; Petersen, AH; Pinto, P; Porteous, ME; Pottinger, C; Pujana, MA; Radice, P; Ramser, J; Rantala, J; Robson, M; Rogers, MT; Ronlund, K; Rump, A; Sanchez de Abajo, AM; Shah, PD; Sharif, S; Side, LE; Singer, CF; Stadler, Z; Steele, L; Stoppa-Lyonnet, D; Sutter, C; Tan, YY; Teixeira, MR; Teule, A; Thull, DL; Tischkowitz, M; Toland, AE; Tommasi, S; Toss, A; Trainer, AH; Tripathi, V; Valentini, V; van Asperen, CJ; Venturelli, M; Viel, A; Vijai, J; Walker, L; Wang-Gohrke, S; Wappenschmidt, B; Whaite, A; Zanna, I; Offit, K; Thomassen, M; Couch, FJ; Schmutzler, RK; Simard, J; Easton, DF; Chenevix-Trench, G; Antoniou, AC; Ottini, L; Consortium of Investigators of Modifiers of BRCA1 and; BRCA2

Author(s): Barnes, DR; Silvestri, V; Leslie, G; McGuffog, L; Dennis, J; Yang, X; Adlard, J; Agnarsson, BA; Ahmed, M; Aittomaki, K; Andrulis, IL; Arason, A; Arnold, N; Auber, B; Azzollini, J; Balmana, J; Barkardottir, RB; Barrowdale, D; Barwell, J; Belotti, M; Benitez, J; Berthet, P; Boonen, SE; Borg, A; Bozsik, A; Brady, AF; Brennan, P; Brewer, C; Brunet, J; Bucalo, A; Buys, SS; Caldes, T; Caligo, MA; Campbell, I; Cassingham, H; Christensen, LL; Cini, G; Claes, KBM; GEMO Study Collaborators; EMBRACE Collaborators; Cook, J; Coppa, A; Cortesi, L; Damante, G; Darder, E; Davidson, R; de la Hoya, M; De Leeneer, K; De Putter, R; Del Valle, J; Diez, O; Ding, YC; Domchek, SM; Donaldson, A; Eason, J; Eeles, R; Engel, C; Evans, DG; Feliubadalo, L; Fostira, F; Frone, M; Frost, D; Gallagher, D; Gehrig, A; Giraud, S; Glendon, G; Godwin, AK; Goldgar, DE; Greene, MH; Gregory, H; Gross, E; Hahnen, E; Hamann, U; Hansen, TVO; Hanson, H; Hentschel, J; Horvath, J; kConFab Investigators; HEBON Investigators; Izatt, L; Izquierdo, A; James, PA; Janavicius, R; Jensen, UB; Johannsson, OT; John, EM; Kramer, G; Kroeldrup, L; Kruse, TA; Lautrup, C; Lazaro, C; Lesueur, F; Lopez-Fernandez, A; Mai, PL; Manoukian, S; Matrai, Z; Matricardi, L; Maxwell, KN; Mebirouk, N; Meindl, A; Montagna, M; Monteiro, AN; Morrison, PJ; Muranen, TA; Murray, A; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Nguyen-Dumont, T; Niederacher, D; Olah, E; Olopade, OI; Palli, D; Parsons, MT; Pedersen, IS; Peissel, B; Perez-Segura, P; Peterlongo, P; Petersen, AH; Pinto, P; Porteous, ME; Pottinger, C; Pujana, MA; Radice, P; Ramser, J; Rantala, J; Robson, M; Rogers, MT; Ronlund, K; Rump, A; Sanchez de Abajo, AM; Shah, PD; Sharif, S; Side, LE; Singer, CF; Stadler, Z; Steele, L; Stoppa-Lyonnet, D; Sutter, C; Tan, YY; Teixeira, MR; Teule, A; Thull, DL; Tischkowitz, M; Toland, AE; Tommasi, S; Toss, A; Trainer, AH; Tripathi, V; Valentini, V; van Asperen, CJ; Venturelli, M; Viel, A; Vijai, J; Walker, L; Wang-Gohrke, S; Wappenschmidt, B; Whaite, A; Zanna, I; Offit, K; Thomassen, M; Couch, FJ; Schmutzler, RK; Simard, J; Easton, DF; Chenevix-Trench, G; Antoniou, AC; Ottini, L; Consortium of Investigators of Modifiers of BRCA1 and; BRCA2;
Details: Publication Year 2022-01-11,Volume 114,Issue #1,Page 109-122
Journal Title: Journal of the National Cancer Institute
Publication Type: Research article
Abstract: BACKGROUND: Recent population-based female breast cancer and prostate cancer polygenic risk scores (PRS) have been developed. We assessed the associations of these PRS with breast and prostate cancer risks for male BRCA1 and BRCA2 pathogenic variant carriers. METHODS: 483 BRCA1 and 1318 BRCA2 European ancestry male carriers were available from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). A 147-single nucleotide polymorphism (SNP) prostate cancer PRS (PRSPC) and a 313-SNP breast cancer PRS were evaluated. There were 3 versions of the breast cancer PRS, optimized to predict overall (PRSBC), estrogen receptor (ER)-negative (PRSER-), or ER-positive (PRSER+) breast cancer risk. RESULTS: PRSER+ yielded the strongest association with breast cancer risk. The odds ratios (ORs) per PRSER+ standard deviation estimates were 1.40 (95% confidence interval [CI] =1.07 to 1.83) for BRCA1 and 1.33 (95% CI = 1.16 to 1.52) for BRCA2 carriers. PRSPC was associated with prostate cancer risk for BRCA1 (OR = 1.73, 95% CI = 1.28 to 2.33) and BRCA2 (OR = 1.60, 95% CI = 1.34 to 1.91) carriers. The estimated breast cancer odds ratios were larger after adjusting for female relative breast cancer family history. By age 85 years, for BRCA2 carriers, the breast cancer risk varied from 7.7% to 18.4% and prostate cancer risk from 34.1% to 87.6% between the 5th and 95th percentiles of the PRS distributions. CONCLUSIONS: Population-based prostate and female breast cancer PRS are associated with a wide range of absolute breast and prostate cancer risks for male BRCA1 and BRCA2 carriers. These findings warrant further investigation aimed at providing personalized cancer risks for male carriers and informing clinical management.
Keywords: Aged, 80 and over; BRCA1 Protein/genetics; BRCA2 Protein/genetics; *Breast Neoplasms/epidemiology/genetics; Genetic Predisposition to Disease; Heterozygote; Humans; Male; Mutation; Polymorphism, Single Nucleotide; *Prostatic Neoplasms/epidemiology/genetics; Risk Assessment; Risk Factors
Department(s): Laboratory Research; Familial Cancer Centre
PubMed ID: 34320204
Publisher's Version: https://doi.org/10.1093/jnci/djab147
Open Access at Publisher's Site: https://doi.org/10.1093/jnci/djab147
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-09-26 05:45:31

Last Modified: 2024-09-26 05:48:04